Pear Therapeutics Plans To Accelerate Reimbursement For Digital Therapeutics With $80M Series D
Executive Summary
The company will use the proceeds to market its three FDA-cleared prescription digital therapeutics.
You may also be interested in...
Finance Watch: Five Biopharma IPOs Bring US Total To 60 In 2021
Public Company Edition: Almost halfway through the year, initial public offerings equal nearly three-quarters of the 2020 total. Also, Pardes is one of four new SPAC mergers; HUTCHMED launched an IPO in Hong Kong; and Zentalis, Theravance and BioXcel launched follow-on offerings.
Exec Chat: Pear Therapeutics’ CEO Charts Future For Digital Therapeutics Following SPAC Deal
Pear has commercialized FDA-cleared prescription digital therapeutics for substance abuse disorder, opioid use disorder and chronic insomnia and has 14 more in development. CEO Corey McCann explained Pear’s vision for how PDTs can transform health care.
Menopause Research To Benefit From White House Initiative To Bolster Women’s Health
Women’s health leaders in the menopause space have high hopes that President Biden’s executive order will provide dollars for more research on how hormone therapy can prevent disease and draw attention to the need for provider education on menopausal symptoms.